Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Volitionrx (VNRX) Shares Outstanding (2016 - 2025)

Volitionrx filings provide 11 years of Shares Outstanding readings, the most recent being $125.8 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 30.89% to $125.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $125.8 million, a 30.89% increase, with the full-year FY2025 number at $125.8 million, up 30.89% from a year prior.
  • Shares Outstanding hit $125.8 million in Q4 2025 for Volitionrx, up from $109.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $125.8 million in Q4 2025 to a low of $52.9 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $78.2 million (2023), compared with a mean of $76.6 million.
  • Biggest five-year swings in Shares Outstanding: increased 1.32% in 2022 and later skyrocketed 45.11% in 2023.
  • Volitionrx's Shares Outstanding stood at $53.8 million in 2021, then rose by 7.63% to $57.9 million in 2022, then skyrocketed by 41.51% to $81.9 million in 2023, then grew by 17.34% to $96.1 million in 2024, then surged by 30.89% to $125.8 million in 2025.
  • The last three reported values for Shares Outstanding were $125.8 million (Q4 2025), $109.6 million (Q3 2025), and $104.0 million (Q2 2025) per Business Quant data.